Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
In a randomised, double-blind trial, high-dose psilocybin administered within a meditation and spiritual-practice programme produced enduring (six-month) increases in prosocial attitudes and behaviours and in healthy psychological functioning (e.g. interpersonal closeness, gratitude, meaning, forgiveness, daily spiritual experiences). Lasting change was predicted by the intensity of the psilocybin-occasioned mystical-type experience and by participants' continued rates of meditation/spiritual practice.
Authors
- Roland Griffiths
- Matthew Johnson
- Frederick Barrett
Published
Abstract
Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2) with moderate-level (“standard”) support for spiritual-practice (LD-SS); (2) high-dose (20 and 30 mg/70 kg on sessions 1 and 2, respectively) with standard support (HD-SS); and (3) high-dose (20 and 30 mg/70kg on sessions 1 and 2, respectively) with high support for spiritual practice (HD-HS). Psilocybin was administered double-blind and instructions to participants/staff minimized expectancy confounds. Psilocybin was administered 1 and 2 months after spiritual-practice initiation. Outcomes at 6 months included rates of spiritual practice and persisting effects of psilocybin. Compared with low-dose, high-dose psilocybin produced greater acute and persisting effects. At 6 months, compared with LD-SS, both high-dose groups showed large significant positive changes on longitudinal measures of interpersonal closeness, gratitude, life meaning/purpose, forgiveness, death transcendence, daily spiritual experiences, religious faith and coping, and community observer ratings. Determinants of enduring effects were psilocybin-occasioned mystical-type experience and rates of meditation/spiritual practices. Psilocybin can occasion enduring trait-level increases in prosocial attitudes/behaviors and in healthy psychological functioning.
Research Summary of 'Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors'
Introduction
Quantum change experiences are described as sudden, deeply meaningful events that can produce broad, lasting changes in emotions, cognition and behaviour. Earlier experimental work has shown that under supportive conditions psilocybin reliably occasions mystical-type experiences that participants often attribute to enduring improvements in well-being, but prior controlled studies in healthy volunteers have provided limited evidence for persistent changes on well-validated trait measures. The authors note that older clinical reports and recent therapeutic trials (for example in cancer-related distress) suggest potential for longer-term benefits, but systematic, prospective investigation of enduring trait-level changes in healthy people has been sparse. This study sought to test whether psilocybin dose and the intensity of support for a structured programme of meditation and other spiritual practices produce enduring positive changes in prosocial attitudes, behaviours, and psychological functioning. Griffiths and colleagues randomised healthy participants into three groups (very low-dose with standard support; high-dose with standard support; high-dose with high support), administered two double-blind psilocybin sessions about one month apart after initiation of spiritual practices, and assessed acute effects, participant attributions, engagement with spiritual practice, and a battery of longitudinal trait measures up to 6 months after baseline. The design therefore aimed to examine both pharmacological and contextual (practice/support) determinants of lasting change.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49-69. https://doi.org/10.1177/0269881117731279
References (13)
Papers cited by this study that are also in Blossom
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Show all 13 referencesShow fewer
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2017)
Cited By (141)
Papers in Blossom that reference this study
Stocker, K., Hartmann, M., Barrett, F. S. et al. · Religion, Brain & Behavior (2026)
Schlomberg, J. T. T., Meling, D., Grylka, R. et al. · Scientific Reports (2026)
Fabiano, N., Stubbs, B., Lawrence, D. W. et al. · Discover Mental Health (2026)
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)
Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L. et al. · Therapeutic Advances in Psychopharmacology (2025)
Perkins, D., Halman, A., Urokohara, A. et al. · Scientific Reports (2025)
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Egger, K., Meling, D., Polat, F. et al. · Imaging Neuroscience (2025)
Roseby, W., Kettner, H., Roseman, L. et al. · Frontiers in Psychology (2025)
Show all 141 papersShow fewer
Aday, J. S., Mcafee, J., Conroy, D. A. et al. · Frontiers in Pain Research (2025)
Modzelewski, S., Waszkiewicz, N., Lukasiewicz, K. et al. · Neuropharmacology (2025)
Zeifman, R. J., Spriggs, M. J., Kettner, H. et al. · Scientific Reports (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Ruban, A., Magnuski, M., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)
Lewis, B. R., Hendrick, J., Byrne, K. et al. · PLOS Medicine (2025)
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)
Jiwani, Z., Goldberg, S. B., Stroud, J. et al. · MedRvix (2024)
Holze, F., Gasser, P., Müller, F. et al. · BJPsych Open (2024)
Polito, V., Liknaitzky, P. · Journal of Psychopharmacology (2024)
Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)
Letheby, C. · Neuroethics (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Psychoactive Drugs (2024)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
Agin-Liebes, G. I., Nielson, E. M., Zingman, M. et al. · Psychology of Addictive Behaviors (2024)
Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Simonsson, O., Osika, W., Stenfors, C. U. D. et al. · Psychological Medicine (2023)
Apud, I., Scuro, J., Rodríguez, L. et al. · Journal of Psychoactive Drugs (2023)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Xin, Y., Armstrong, S. B., Averill, L. A. et al. · Psychology of Consciousness Theory Research and Practice (2023)
Zeifman, R. J., Kettner, H., Pagni, B. A. et al. · Scientific Reports (2023)
Kamilar-Britt, P., Gordis, E. B., Earleywine, M. · Psychedelic Medicine (2023)
Herrmann, Z., Levin, A. W., Cole, S. P. et al. · Psychedelic Medicine (2023)
Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)
Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Newton, K., Moreton, S. G. · Ecopsychology (2023)
Ort, A., Smallridge, J. W., Sarasso, S. et al. · iScience (2023)
Kangaslampi, S. · Journal of Psychedelic Studies (2023)
Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A. et al. · Frontiers in Psychiatry (2023)
Moreton, S. G., Arena, A. F., Foy, Y. et al. · Death Studies (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Devenot, N., Seale-Feldman, A., Smith, E. et al. · Kennedy Institute of Ethics Journal (2022)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Madsen, M. K., Ozenne, B., Armand, S. et al. · Frontiers in Psychology (2022)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Barba, T., Buehler, S., Kettner, H. et al. · BJPsych Open (2022)
Swee, M. B., Nayak, S., Hurwitz, E. et al. · PLOS ONE (2022)
Henningfield, J. E., Coe, M. A., Griffiths, R. R. et al. · Neuropharmacology (2022)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)
Ruffell, S. G. D., Gandy, S., Tsang, W. et al. · Psyarxiv (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Amada, N., Shane, J. · Journal of Humanistic Psychology (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Nayak, S., Griffiths, R. R. · Frontiers in Psychology (2022)
Gandy, S. · Journal of Psychedelic Studies (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)
Gaddis, A., Lidstone, D. E., Nebel, M. B. et al. · Biorxiv (2022)
Markopoulos, A., Inserra, A., De Gregorio, D. et al. · Frontiers in Pharmacology (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
Simonsson, O., Goldberg, S. B. · Journal of Psychoactive Drugs (2022)
Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)
Polito, V., Liknaitzky, P. · Psyarxiv (2021)
Niles, H., Fogg, C., Kelmendi, B. et al. · BMC Palliative Care (2021)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Pace, B. A., Devenot, N. · Frontiers in Psychology (2021)
Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)
Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L. et al. · Frontiers in Psychology (2021)
Cavanna, F., Pallavicini, C., Milano, V. et al. · Journal of Psychedelic Studies (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Yehuda, R., Lepow, L., Morishita, H. · Frontiers in Neuroscience (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
McGovern, H., Leptourgos, P., Hutchinson, B. et al. · Psyarxiv (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Lebedev, A. V., Acar, K., Garzón, B. et al. · Scientific Reports (2021)
Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Healy, C. J., Lee, K. A. · Chronic Stress (2021)
Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Qiu, T. T., Minda, J. P. · Psyarxiv (2021)
Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Bright, S. J., Gringart, E., Blatchford, E. et al. · Australian Journal of Psychology (2020)
Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Greif, A., Šurkala, M. · Medicine Health Care and Philosophy (2020)
Bornemann, J. · Journal of Psychoactive Drugs (2020)
Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)
Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Forstmann, M., Yudkin, D. A., Prosser, A. M. B. et al. · PNAS (2020)
Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Barsuglia, J. P., Davis, A. K., Palmer, R. et al. · Frontiers in Psychology (2018)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.